Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cornelius Kortsik"'
Autor:
Monika Serke, Petra Neuser, Niels Reinmuth, Michael Thomas, Philipp A. Schnabel, Alexander Reuss, Martin Wolf, Cornelius Kortsik, Jürgen Fischer, Piotr Czapiewski, Stefan Andreas, Matthias Villalobos
Publikováno v:
Oncology Letters
The aim of the present study was to assess the expression of epithelial-mesenchymal transition biomarkers (E-cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non-squamous non-small cell lung
Autor:
Jürgen Fischer, Monika Serke, Martin Wolf, Alexander Reuss, Niels Reinmuth, Cornelius Kortsik, Philipp A. Schnabel, Petra Neuser, Michael Thomas, Piotr Czapiewski, Matthias Villalobos, Stefan Andreas
Publikováno v:
Medical oncology (Northwood, London, England). 35(7)
Prior studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy. The aim
Autor:
Christian Witt, Thomas Acker, Jens Kollmeier, Ernst Müller, Michael Schenk, Martin Wolf, Michael Thomas, Philipp A. Schnabel, Roland Penzel, Jürgen Fischer, Alexander Reuss, Michael Schröder, Cornelius Kortsik, Stefan Andreas, Michael von Eiff, Monika Serke, Matthias Villalobos, Niels Reinmuth, Christian Grah
Publikováno v:
European Respiratory Journal. 46:219-229
Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination comp
Autor:
Ulrich Gatzemeier, Igor Bondarenko, Yevhen Hotko, Jae Kyung Roh, Christopher Stroh, Cornelius Kortsik, Kenneth J. O'Byrne, Rodryg Ramlau, Carlos H. Barrios, Corinna Eschbach, Robert Pirker, Chih Teng Yu, Armin Schueler, Uwe M. Martens, Luis Paz-Ares, Joachim von Pawel, José Rodrigues Pereira, Ilhan Celik
Publikováno v:
The Lancet Oncology. 12:795-805
Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced n
Autor:
Michael Thomas, Juergen R. Fischer, Philipp A. Schnabel, Christian Grah, Stefan Andreas, Dirk Behringer, Niels Reinmuth, R. Heine, Alexander Reuss, Monika Serke, Christian Witt, Cornelius Kortsik, M. Schroeder, Jens Kollmeier, Ernst Müller, M. Schenk, Martin Wolf, Thomas Acker, L. J. Müller, M. von Eiff
Publikováno v:
Journal of Clinical Oncology. 29:7504-7504
7504 Background: Combining EGFR kinase inhibition (E) with an anti-VEGF strategy (B) showed promising activity (RR 20%; PFS 6.2 months) in recurrent NS-NSCLC (J Clin Oncol (2005) 23: 2544). To asse...